Promoting innovation was a key issue highlighted at the Medicines and Healthcare products Regulatory Agency’s (MHRA) 8th Annual Lecture last Monday evening (11 March) at the Royal College of Physicians in London.
Sir Andrew Witty, Chief Executive of GlaxoSmithKline (GSK), encouraged the MHRA and other regulators to work together to stimulate innovation. He called for the MHRA to use its voice globally to ensure that other regulators are aligned, enabling productivity, efficiency savings and speedy access to new innovative medicines and products. Sir Andrew also spoke about GSK’s redesigned approach to research and development, new manufacturing technologies being explored and the company’s continued commitment to clinical trials transparency.
Professor Sir Kent Woods, Chief Executive of the MHRA, responded by highlighting the MHRA’s commitment to promoting innovation through its expert group and by providing early advice about the regulatory system so that new medicines and products can be developed faster and made available to people sooner.
He added: “We are committed to promoting innovation and helping industry to develop new medicines and products for people that are safe and effective. “That’s why we have launched an Internet-based Innovation Office to provide early-stage advice about the regulatory process to organisations that are developing innovative medicines or medical devices. “Our expert group on innovation is overseeing a programme of activities, including work on adaptive licensing, early access to medicines, the regulation of advanced manufacturing and how we can improve our response to regulatory innovations in future. “We have also invested in new software that will help our inspections team to better prioritise their inspections. By targeting their activity to the areas of greatest risk they will better protect public health and reduce the overall administrative and economic burden on industry.”
Over 350 stakeholders from a range of different health and science organisations attended the event that was used to formally introduce the new MHRA family that includes the Clinical Practice Research Datalink (CPRD) and from 1 April, the National Institute for Biological Standards and Control (NIBSC).